What Calprofen Treats: Main Uses and Benefits

Calprofen is commonly used across therapeutic domains, playing a role in managing elevated body temperature in children, commonly known as fever. This supportive action provides assistance that helps ease the overall symptom burden of distress and general malaise associated with a febrile state, and contributes to easing discomfort during episodes of illness or post-immunisation reactions. The medicine is used to reduce a high temperature (fever) when a child feels distressed or unwell.

It offers crucial analgesic support, applied when temporary relief from mild to moderate pain is needed. Specific indications for use include symptomatic relief for headache, generalized body aches, pain from toothache, sore throat, earache, and discomfort associated with teething pain. The aim is to provide symptomatic assistance that supports patients during difficult episodes by easing distress related to acute, short-term pain manifestations.

The medicine is also relevant across therapeutic areas involving heightened tissue response, applied for symptoms related to localized inflammation, swelling, and tenderness. The medicine is considered relevant for offering supportive relief when symptoms related to physical discomfort and systemic imbalance become more noticeable.

---

Context of Use: Addressing Symptom Clusters

The medicine is relevant for easing symptoms that cluster into patterns requiring supportive management, focusing on acute episodes where short-term symptomatic assistance is important. It helps manage symptoms that create noticeable physiological strain, supporting general well-being during symptomatic phases.

This section summarizes the official population eligibility and contraindications for Calprofen (Ibuprofen oral suspension), as defined by regulatory authorities. The information is based strictly on governmental prescribing documents.

Approved and Restricted Populations

Eligibility Category	Status	Regulatory Criteria
Approved Pediatric Use	Allowed	Children aged 3 months and older with a body weight over 5 kg. Use is not recommended for children under 3 months of age.
Pregnancy	Contraindicated	Use is strictly prohibited in the last trimester. Should be used with caution during the first and second trimesters.
Lactation	Permitted	Ibuprofen is excreted into breast milk in small amounts and is generally considered acceptable for use while breastfeeding.
Organ Impairment	Restricted	Use requires caution in patients with pre-existing impaired renal or hepatic function, and in those with uncontrolled hypertension or heart failure (NYHA Class II-III).

Absolute Contraindications

The medicine must not be used by individuals with the following official contraindications:

• Hypersensitivity to ibuprofen, aspirin, or any other non-steroidal anti-inflammatory drugs (NSAIDs).
• Active or history of recurrent peptic ulceration or gastrointestinal bleeding.
• Severe heart failure (NYHA Class IV), severe renal failure, or severe hepatic failure.
• Concurrent use of other NSAID painkillers or high-dose aspirin.

Contraindicated Combinations and Additive Risks

The combination of Calprofen with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 selective inhibitors, is formally restricted due to the established additive risk of serious gastrointestinal adverse events. Co-administration with anticoagulants such as Warfarin, oral corticosteroids, or anti-platelet agents carries a documented risk of enhanced bleeding and gastrointestinal ulceration. The consumption of alcohol is also associated with an increased risk of stomach bleeding. Ibuprofen use is formally contraindicated for peri-operative pain management in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Drug Exposure and Clearance Changes

Ibuprofen is officially documented to interfere with the clearance of certain medicines. Co-use with agents like Lithium and Methotrexate may reduce their renal clearance, potentially leading to increased plasma concentrations of these drugs. Similarly, plasma levels of cardiac glycosides (e.g., Digoxin) may increase. The therapeutic effect of several antihypertensives and diuretics may be reduced during co-administration.

Mandatory Administration Constraints

To mitigate the interference with cardioprotective low-dose aspirin, specific timing constraints are necessary. Regulatory guidelines mandate that Ibuprofen must be administered at least eight hours before or thirty minutes after the immediate-release aspirin dose. Furthermore, official labeling includes population-specific warnings: an increased risk of renal impairment is noted in dehydrated children and adolescents and in elderly patients receiving concurrent treatment.

The mechanism of action for Calprofen is dependent on its active ingredient, Ibuprofen, which functions as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzyme pathway. This action influences enzyme activity and subsequent mediator production in both central and peripheral pathways.

Enzyme Target and Pathway Disruption

The medicine’s primary mechanism involves temporarily blocking the activity of the COX-1 and COX-2 enzymes. This targeted inhibition limits the conversion of arachidonic acid into prostaglandins (PGs) and other prostanoid mediators. This molecular modification restricts the formation of mediators that act as peripheral nociceptor sensitizers and that alter the central thermoregulatory set point.

Central and Peripheral Signal Control

This mechanistic domain involves actions in both the central nervous system (CNS) and peripheral tissues. The drug's mechanism reduces PGE2 synthesis within the hypothalamus, which permits the resetting of the elevated temperature set point. Concurrently, reducing local PG concentrations at affected tissues limits the chemical sensitization of peripheral nociceptors and modulates vascular responses.

Inherent Mechanistic Constraints

Ibuprofen's non-selective mechanism inherently includes the inhibition of COX-1, which is responsible for homeostatic PG production necessary for maintaining the gastric mucosal layer. This physiological consequence is an inherent component of the non-selective enzyme-targeting design and is not related to the mechanism of action producing the antipyretic or analgesic effects.

Calprofen is a liquid formulation of Ibuprofen intended for oral administration only. The medicine is presented as an Oral Suspension containing 100 mg of Ibuprofen per 5 ml, and its use is strictly limited to short-term symptomatic management.

Administration and Preparation

To ensure an accurate dose, the bottle must be shaken vigorously before each use. Dosing requires the use of the measuring device supplied with the pack, as standard household spoons are not appropriate for precise pediatric dosing. The suspension can be taken without regard to meals, but taking it with food is suggested if the child has a sensitive stomach.

Dosing and Frequency

Dosing is based on the child's age and body weight, with a general principle of using the lowest effective dose for the shortest duration necessary. The typical schedule requires administration three to four times per day, constrained by a mandatory minimum interval of four hours between successive doses. The total daily intake should generally not exceed 20 mg per kilogram of body weight. The specific protocol for post-immunisation fever involves a maximum of two doses within a 24-hour period.

Age and Duration Constraints

The suspension is not approved for children under 3 months of age or those weighing less than 5 kg. For infants 3 to 6 months, the duration of use is strictly limited to 24 hours. For all children 6 months and older, the maximum continuous course of administration is three days.

Research evidence / Overview of studies for Calprofen

This section provides an overview of the research that has explored Ibuprofen, the active ingredient in Calprofen, focusing on the types of studies conducted and the patterns of change observed, without offering clinical recommendations or individual advice.

---

Evidence for Managing Elevated Body Temperature (Fever)

Research examined Ibuprofen in study settings exploring fever, a condition involving temporary physiological imbalance. The evidence base consists primarily of Randomized Controlled Trials (RCTs) across various pediatric ages. These studies monitored objective outcomes, including the magnitude of temperature change and the time elapsed before a lower temperature was documented, describing patterns observed in comparison to control groups. The existing body of evidence related to objective temperature outcomes is designated as High in certainty, however, research highlights specific aspects where certainty remains limited, such as in measures of overall patient-reported discomfort.

---

Evidence for Acute Mild to Moderate Pain

Ibuprofen was studied for its use in research exploring acute outcomes related to physical discomfort from conditions like headache, earache, toothache, and post-procedural discomfort. RCTs across a wide pediatric range explored short-term symptom changes. Main outcomes examined were the degree of change in pain intensity using patient- or parent-reported scales. Findings describe patterns observed regarding the time needed for reported relief and the proportion of children achieving predefined changes in discomfort. The body of evidence for acute pain is designated as Moderate in certainty, due to factors such as documented variability in study outcomes in the standardized metrics used.

---

Long-Term Studies and Follow-Up Duration

Research exploring the patterns of change observed following administration has primarily focused on short-term symptom changes, with typical follow-up durations limited to the first 24 hours post-dose for pain and fever outcomes. While safety observations were associated with studies tracking participants up to approximately 28 days, these extended observations do not constitute a full body of evidence on long-term functional outcomes. Information on the durability of the response is generally not fully established by the core efficacy trials.

---

Evidence in Pediatric Subgroups

The core research base included children starting from six months of age and older. Studies monitored responses in various age groups, encompassing specific research exploring infants and toddlers as a distinct subgroup. Findings describe group patterns related to these ages, but the results apply only to the populations studied and do not necessarily extend to children not included in the trials.

---

What is Still Uncertain About Calprofen Research

The evidence highlights known limitations. Key research limitation frames include acknowledged variability in study designs and measurement tools, particularly when assessing outcomes related to systemic imbalance, such as overall comfort. Evidence is limited regarding long-term effects. Comparative evidence is also lacking for specific scenarios, such as the use of the drug in combination or alternation with other common relievers, demonstrating known limitations in the current evidence landscape.

Key Studies & References

1. Assessment and initial management of fever in children under 5 years: NICE Guideline NG143

Common questions about Calprofen (FAQ)

---

Q: Why is Calprofen only for children?

A: Calprofen is a specific liquid formulation approved and primarily labeled for use in the pediatric population from three months of age. Official product documents contain directions and warnings specific to the needs of children and are not intended for adult use.

---

Q: How quickly should Calprofen start working?

A: Regulatory sources for the active ingredient, ibuprofen, indicate that it can begin the process of reducing fever starting in as little as 15 minutes. However, the time it takes to see a full effect can vary between individuals.

---

Q: How long does the effect of Calprofen usually last?

A: Official product information suggests that the medicine may provide effective relief from fever for up to 8 hours in some cases. The typical duration of the medicine's effect guides the minimum time recommended between successive doses.

---

Q: Can Calprofen be given to a child who is taking other daily medications?

A: Official drug labeling notes the importance of seeking guidance from a medical professional if the child is under a doctor's care for any serious condition or is taking any other drug. This is due to the potential for interactions that may change how each drug works.

---

Q: What is the difference between Ibuprofen and Paracetamol, which are both used in children's medicines?

A: The active ingredient in Calprofen, ibuprofen, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID), which helps relieve pain, fever, and inflammation. Official sources classify paracetamol (also called acetaminophen) as a pain reliever and fever reducer that does not belong to the NSAID class.

---

Q: Is it true that Calprofen can worsen symptoms of chickenpox?

A: Official regulatory documents indicate that the active ingredient, ibuprofen, is restricted from use in children who have chickenpox (varicella). This restriction is due to an established, though rare, risk of severe skin infections.

---

Q: What is the maximum number of days a child can typically use Calprofen?

A: The maximum duration of continuous use depends on the child's age. For infants aged 3 to 6 months, use is limited to a maximum of 24 hours. For children aged 6 months and older, the medicine should generally not be used for more than 3 days without professional medical guidance.

---

Q: Is Calprofen considered a strong medicine?

A: The medicine is classified as an over-the-counter (OTC) Non-Steroidal Anti-Inflammatory Drug (NSAID) used for the short-term symptomatic treatment of mild to moderate pain and fever. This classification means it is approved as an over-the-counter option for managing common conditions.

---

Q: Are there different forms of Calprofen (e.g., tablets, liquid)?

A: The Calprofen brand is primarily known for its liquid Oral Suspension formulation designed specifically for children. Product information also describes the availability of the suspension in single-use sachets containing a measured dose.

---

Q: Is it normal for a child to feel sleepy after taking Calprofen?

A: Official product information on the active ingredient is associated with the possibility of drowsiness as a known, though uncommon, side effect affecting the nervous system. The term 'uncommon' typically means it may affect up to 1 in 100 people.

---

Q: Does Calprofen affect alertness or concentration?

A: Official product information lists effects such as dizziness and drowsiness as possible side effects. These effects, if they occur, may temporarily affect alertness or coordination and are categorized as an uncommon occurrence.

---

Q: Can Calprofen be taken by adults, even if it's marketed for children?

A: While the active ingredient, ibuprofen, is available in adult medicines, the specific Calprofen product is formulated and labeled for children. The labeling indicates that the product is not labeled with directions or complete warnings for adult use.

---

Q: What is the purpose of the flavoring in the liquid Calprofen?

A: The flavoring ingredient, such as strawberry flavor, is included as an excipient in the Oral Suspension. This is done to help make the medicine more palatable and easier for infants and children to take.

---

Q: Are there specific food or drinks that should be avoided when giving Calprofen?

A: Official labeling states that the consumption of alcohol is associated with an increased risk of stomach bleeding when taking the active ingredient. Therefore, official warnings describe alcohol as being restricted from use when the active ingredient is in the system.

---

Q: Does Calprofen have sugar in it?

A: According to official regulatory product information, Calprofen Ibuprofen Suspension is specifically formulated as a sugar-free preparation.

---

Q: Why is it described that Calprofen should be used for the shortest time possible?

A: Official regulatory documents stress using the lowest effective dose for the shortest duration necessary to minimize the risk of side effects. This is a general safety principle tied to potential adverse events, particularly those affecting the gastrointestinal or cardiovascular systems.

Storage and Protection Requirements

Official regulatory labeling dictates that Calprofen Ibuprofen Suspension must be stored within a controlled environment to maintain its stability. The medicine must be kept at room temperature, specifically below 25 C (77 F), and it must not be frozen. The product should be stored in its original container and protected from direct sunlight.

Child-Safety and Disposal

For safety, the medicine must be stored out of the sight and reach of children, and the child-resistant cap must be tightly secured after each use. The medicine should not be used past the expiry date printed on the packaging. Unused or expired Calprofen must not be thrown away via wastewater or household refuse; instead, it should be returned to a pharmacy or disposed of according to local pharmaceutical waste regulations.